Don’t Rush to Aprocitentan for Resistant Hypertension

December 2024

Aprocitentan (Tryvio) will be the first dual endothelin antagonist approved for resistant hypertension.

It blocks receptors of endothelin...a vasoconstrictor and mediator of aldosterone.

Think of it as similar to the other endothelin receptor antagonists, such as bosentan (Tracleer)...but these are for pulmonary arterial hypertension.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Immunizations Give More Adults a Pneumococcal Vaccine
Endocrinology Tackle Ongoing GLP-1 Agonist Questions
Medicare Be Aware of the Medicare Prescription Payment Plan
Hypertension Don’t Rush to Aprocitentan for Resistant Hypertension
Antidepressants Address the Skinny on Antidepressant Weight Gain
Critical Care Don’t Stress Over New Stress Ulcer Prophylaxis Guidelines
Sickle Cell Disease Know Who Should Get Penicillin for Sickle Cell Disease
NatMed Spotlight Be Ready for Questions About Peppermint

Don’t Rush to Aprocitentan for Resistant Hypertension

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents